Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Biotechnol. 2012 Sep;30(9):466-74. doi: 10.1016/j.tibtech.2012.05.006. Epub 2012 Jul 2.

Mass spectrometry imaging is moving toward drug protein co-localization.

Author information

1
Aix-Marseille Universite, CRO2, 13385, Marseille, France; INSERM, UMR 911, 13385 Marseille, France.

Abstract

Mass spectrometry (MS)-based technology provides label-free localization of molecules in tissue samples. Drugs, proteins, lipids and metabolites can easily be monitored in their environment. Resolution can be achieved down to the cellular level (10-20 μm) for conventional matrix-assisted laser desorption/ionization (MALDI) imaging, or even to the subcellular level for more complex technologies such as secondary ionization mass spectrometry (SIMS) imaging. One question remains: are we going to be able to investigate functional relationships between drugs and proteins and compare with localized phenomena? This review describes the various spatial levels of investigation offered by mass spectrometry imaging (MSI), and the advantages and disadvantages compared with other labeling technologies.

PMID:
22762968
DOI:
10.1016/j.tibtech.2012.05.006
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center